BINEX Co., Ltd. (053030.KQ)
KRW 17490.0
(-3.95%)
KRW 17490.0
(-3.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 45.34 Billion KRW | 81.29% |
| 2022 | 25.01 Billion KRW | 6714.88% |
| 2021 | 367.04 Million KRW | -94.11% |
| 2020 | 6.22 Billion KRW | 27.23% |
| 2019 | 4.89 Billion KRW | -56.57% |
| 2018 | 11.27 Billion KRW | -22.14% |
| 2017 | 14.47 Billion KRW | -28.25% |
| 2016 | 20.17 Billion KRW | 100.59% |
| 2015 | 10.05 Billion KRW | 0.0% |
| 2013 | 5.14 Billion KRW | 127.36% |
| 2012 | -18.82 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 64.28 Billion KRW | 24.64% |
| 2024 Q1 | 51.57 Billion KRW | 13.73% |
| 2023 Q2 | 23.38 Billion KRW | -13.99% |
| 2023 Q3 | 37.62 Billion KRW | 60.87% |
| 2023 FY | 45.34 Billion KRW | 81.29% |
| 2023 Q4 | 45.34 Billion KRW | 20.53% |
| 2023 Q1 | 27.19 Billion KRW | 8.71% |
| 2022 Q1 | 4.69 Billion KRW | 1180.01% |
| 2022 Q4 | 25.01 Billion KRW | 14.85% |
| 2022 Q3 | 21.77 Billion KRW | 27.49% |
| 2022 Q2 | 17.08 Billion KRW | 263.62% |
| 2022 FY | 25.01 Billion KRW | 6714.88% |
| 2021 FY | 367.04 Million KRW | -94.11% |
| 2021 Q3 | 18.02 Billion KRW | 79.3% |
| 2021 Q4 | 367.04 Million KRW | -97.96% |
| 2021 Q1 | 2.43 Billion KRW | -59.52% |
| 2021 Q2 | 10.05 Billion KRW | 313.65% |
| 2020 Q4 | 6 Billion KRW | 232.62% |
| 2020 FY | 6.22 Billion KRW | 27.23% |
| 2020 Q3 | -4.52 Billion KRW | -3876.46% |
| 2020 Q2 | 119.9 Million KRW | -98.56% |
| 2020 Q1 | 8.32 Billion KRW | 70.03% |
| 2019 Q2 | 6.06 Billion KRW | 9.51% |
| 2019 FY | 4.89 Billion KRW | -56.57% |
| 2019 Q4 | 4.89 Billion KRW | -8.48% |
| 2019 Q3 | 5.34 Billion KRW | -11.84% |
| 2019 Q1 | 5.54 Billion KRW | -50.85% |
| 2018 FY | 11.27 Billion KRW | -22.14% |
| 2018 Q4 | 11.27 Billion KRW | -30.54% |
| 2018 Q3 | 16.22 Billion KRW | 9.54% |
| 2018 Q2 | 14.81 Billion KRW | 56.45% |
| 2018 Q1 | 9.46 Billion KRW | -34.59% |
| 2017 FY | 14.47 Billion KRW | -28.25% |
| 2017 Q1 | 14.58 Billion KRW | -27.71% |
| 2017 Q2 | 16.87 Billion KRW | 15.66% |
| 2017 Q4 | 14.47 Billion KRW | 10.47% |
| 2017 Q3 | 13.1 Billion KRW | -22.32% |
| 2016 Q2 | 15.4 Billion KRW | 53.05% |
| 2016 FY | 20.17 Billion KRW | 100.59% |
| 2016 Q4 | 20.17 Billion KRW | 59.39% |
| 2016 Q3 | 12.65 Billion KRW | -17.83% |
| 2016 Q1 | 10.06 Billion KRW | -14.99% |
| 2015 Q4 | 11.84 Billion KRW | 0.0% |
| 2015 FY | 10.05 Billion KRW | 0.0% |
| 2014 Q3 | 6.87 Billion KRW | -31.12% |
| 2014 Q1 | 10.97 Billion KRW | 113.18% |
| 2014 Q2 | 9.98 Billion KRW | -9.04% |
| 2013 Q2 | 12.65 Billion KRW | -28.27% |
| 2013 FY | 5.14 Billion KRW | 127.36% |
| 2013 Q4 | 5.14 Billion KRW | -67.33% |
| 2013 Q3 | 15.76 Billion KRW | 24.53% |
| 2013 Q1 | 17.64 Billion KRW | 193.73% |
| 2012 Q4 | -18.82 Billion KRW | -209.81% |
| 2012 FY | -18.82 Billion KRW | 0.0% |
| 2012 Q3 | -6.07 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 198.19% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 211.735% |
| Bioneer Corporation | -3.9 Billion KRW | 1260.438% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -442.967% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -206.106% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -404.314% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 285.654% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 88.341% |
| Medy-Tox Inc. | 49.58 Billion KRW | 8.545% |
| Peptron, Inc. | 4.86 Billion KRW | -831.422% |
| Amicogen, Inc. | 125.26 Billion KRW | 63.798% |
| Genexine, Inc. | 61.39 Billion KRW | 26.139% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 431.323% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 180.9% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 15.349% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 237.674% |
| SillaJen, Inc. | -13.89 Billion KRW | 426.438% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 46.194% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -65.654% |
| Genomictree Inc. | -43.43 Billion KRW | 204.403% |
| MedPacto, Inc. | -64 Billion KRW | 170.855% |
| D&D Pharmatech | -7.5 Billion KRW | 704.004% |
| EASY BIO,Inc. | 53.21 Billion KRW | 14.777% |
| GI Innovation, Inc. | -4.82 Billion KRW | 1040.33% |